Université Paris Descartes

Centre National De La Recherche Scientifique

Université De Rennes 1

Commissariat a L'energie Atomique Et Aux Energies Alternatives

National Institute of Health and Medical Research

The University of Chicago

University Claude Bernard - Lyon 1

Université De Bretagne Occidentale

Centre Nationale De La Recherche Scientifique

Centre Hospitalier Universitaire De Brest

The Rockefeller University

Assistance Publique-Hopitaux De Paris

Sorbonne Université

University Claude Bernard Lyon I

Women & Infants Hospital of Rhode Island

Nassima Oumata

Paul Greengard

Laurent Meijer

Hervé Galons

Karima Bettayeb

Herve Galons

Aloïse Mabondzo

Anne-Cécile Guyot

Christian Berthou

Florence Popowycz

Benoit Joseph

Luc Demange

Deborah J Nelson

Karine Lester

Barbara Stonestreet

Charlotte Leuxe

Narciso Costa

Marc Flajolet

Aida Gabdoulkhakova

Vladimir Riazanski

Alain Pruvost

Clémence Disdier

Thomas Falguieres

Virginie Vauthier

Deborah Nelson

Benoït Joseph

Compound of formula (I) and its addition salts with pharmaceutically acceptable acids, and methods in which an effective amount of the compound or any pharmaceutically acceptable salt thereof is administered (as a medicament) to an individual in need thereof.

Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders

A method for treatment of disease by reduction in macrophages-mediated bacterial killing, including administration to patients in need a compound of formula (I): wherein A is N or CH; B is NO, or S; Ris H, (C-C)alkyl group, methyl(C-C)cycloalkyl group or (C-C)cycloalkyl group; Ris an aryl, arylmethyl group or methylheteroaryl group as methylpyridine and methylthiophene; Ris absent when B is O or S, or is H or (C-C)alkyl group when B is N; Ris (C-C)alkyl group or (C-C)cycloalkyl group, groups bearing a carboxylic acid group, and (C-C)alkyl group or (C-C)cycloalkyl substituted by hydroxyl group, halogen group or methoxy group, when B is N, Rand Rcan together form a 5- or 6-membered heterocycle substituted by carboxylic acid group, substituted by a halogen atom, hydroxyl group, methoxy group or hydroxymethyl group, or pharmaceutically acceptable salt. Also provided are new compounds relating to this use.

Purine derivative compounds for medical use

A compound of formula (I), or a pharmaceutically acceptable salt thereof, where Ris a (C-C)alkyl or (C-C)cycloalkyl group; Ris a (C-C)alkyl, (C-C)cycloalkyl, (C-C)alkenyl, (C-C)fluoroalkyl, (C-C)fluoroalkoxy, or (C-C)alkoxy(C-C)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRRgroup, where Rand Rare independently a hydrogen atom or a (C-C)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; Ris the same as Ror hydrogen; the Rand Rgroups independently being substitutable with an &#x2014;OCORgroup, where Ris a natural or unnatural amino acid derivative or a piperidyl group; alternatively, Rand Rtogether form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and Ris a hydrogen or a (C-C)alkyl group.

[object Object]

The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.

Perharidines as CDK inhibitors

At least one compound of following formula I: 

Use of purine derivatives for the manufacture of a medicament

Growing community of inventors

Paris, France

Nassima Oumata